These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35276694)

  • 1. Mechanisms of GZ17-6.02 resistance.
    Booth L; West C; Von Hoff D; Dent P
    Anticancer Drugs; 2022 Jun; 33(5):415-423. PubMed ID: 35276694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy.
    Booth L; Roberts JL; West C; Von Hoff D; Dent P
    J Cell Physiol; 2020 Nov; 235(11):8098-8113. PubMed ID: 31951027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GZ17-6.02 kills PDX isolates of uveal melanoma.
    Booth L; Roberts JL; Spasojevic I; Baker KC; Poklepovic A; West C; Kirkwood JM; Dent P
    Oncotarget; 2024 May; 15():328-344. PubMed ID: 38758815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GZ17-6.02 and axitinib interact to kill renal carcinoma cells.
    Booth L; West C; Moore RP; Hoff DV; Dent P
    Oncotarget; 2022; 13():281-290. PubMed ID: 35136485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells.
    Booth L; West C; Von Hoff D; Kirkwood JM; Dent P
    Front Oncol; 2021; 11():656453. PubMed ID: 33898322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells.
    Booth L; Roberts JL; West C; Dent P
    Oncotarget; 2024 Mar; 15():159-174. PubMed ID: 38441437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells.
    Booth L; West C; Moore RP; Von Hoff D; Dent P
    Oncotarget; 2022; 13():92-104. PubMed ID: 35035775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells.
    Booth MR; Booth L; Roberts JL; West C; Dent P
    Oncotarget; 2024 Feb; 15():124-133. PubMed ID: 38329728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
    Booth L; Roberts JL; Tavallai M; Webb T; Leon D; Chen J; McGuire WP; Poklepovic A; Dent P
    Oncotarget; 2016 Apr; 7(15):19620-30. PubMed ID: 26934000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins.
    Booth L; West C; Moore RP; Von Hoff D; Dent P
    Front Oncol; 2021; 11():711043. PubMed ID: 34490108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate].
    Dent P; Booth L; Poklepovic A; Hoff DV; Hancock JF
    Cell Signal; 2020 Apr; 68():109525. PubMed ID: 31911180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GZ17-6.02 kills prostate cancer cells
    Booth L; Roberts JL; West C; Dent P
    Front Oncol; 2022; 12():1045459. PubMed ID: 36408163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent Antitumor Effects of a Combination of Three Nutraceutical Compounds.
    Vishwakarma V; New J; Kumar D; Snyder V; Arnold L; Nissen E; Hu Q; Cheng N; Miller D; Thomas AR; Shnayder Y; Kakarala K; Tsue TT; Girod DA; Thomas SM
    Sci Rep; 2018 Aug; 8(1):12163. PubMed ID: 30111862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivo.
    Dent P; Booth L; Roberts JL; Poklepovic A; Hancock JF
    J Cell Physiol; 2020 Oct; 235(10):6862-6874. PubMed ID: 31985048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
    Huang X; Wang S; Lee CK; Yang X; Liu B
    Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.
    Booth L; Roberts JL; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(1):109-121. PubMed ID: 30142009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling.
    Booth L; West C; Hoff DV; Dent P
    Front Oncol; 2020; 10():1331. PubMed ID: 32983965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
    Booth L; Poklepovic A; Dent P
    Biochem Pharmacol; 2020 Aug; 178():114067. PubMed ID: 32504550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.
    Chen X; Yeung TK; Wang Z
    Biochem Biophys Res Commun; 2000 Nov; 277(3):757-63. PubMed ID: 11062025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma.
    Choi J; Bordeaux ZA; McKeel J; Nanni C; Sutaria N; Braun G; Davis C; Miller MN; Alphonse MP; Kwatra SG; West CE; Kwatra MM
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.